'Echocardiography' p5 Searchterm 'Echocardiography' found in 31 articles 7 terms [ • ] - 24 definitions [• ] Result Pages : •
Imagent® is an injectable suspension for intravenous administration during a sonogram. This diagnostic contrast agent for enhancement of ultrasound images contains perflexane lipid microspheres. Imagent® US is indicated in the assessment of heart function and perfusion, as well as the detection of tumors and blood flow abnormalities by using gray scale, color Doppler, and harmonic ultrasound imaging techniques. During the course of its development, the brand name for this product has changed from Imagent to Imavist (between August 2000 and March 2002) back to Imagent. The manufacturer's 06/03/02 press release announcing FDA approval refers to the product as 'Imagent (formerly Imavist),' and the approval notice and monograph posted at the FDA site refers to the product as Imagent. Jointly developed by Alliance Pharmaceutical Corp and Bayer Schering Pharma AG (Germany). Source: PR Newswire - 10/10/96, 03/31/98, 10/13/99, 03/13/01, 10/08/01; FDA approvals - 05/31/02; Alliance Pharmaceutical press release - 06/03/02. Currently the production of Imagent® is discontinued.
Drug Information and Specification
RESEARCH NAME
AF0150
DEVELOPER
IMCOR Pharmaceuticals, Inc.
INDICATION
APPLICATION
Intravenous
TYPE
Lipid: DMPC
CHARGE
Neutral
Perfluorohexane/Nitrogen
MICROBUBBLE SIZE
99.8% < 10μm
PRESENTATION
-
STORAGE
Room Temp 15−30 °C
PREPARATION
Reconstitute with 10 ml water
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT! •
Lateral resolution is the minimum separation of two interfaces aligned along a direction perpendicular (objects that are side by side) to the ultrasound beam. The lateral or angular resolution directly relates with the collimation of the beam emitted by the crystal. Lateral resolution is proportionally affected by the frequency, the higher the frequency the greater the lateral resolution.
Higher frequency transducers are used in fetal and pediatric echocardiography because the lateral resolution displays the smaller structures better. Lower frequencies are used for adults where structures are larger and the need for greater depth penetration is important. Further Reading: Basics: •
From Bayer Schering Pharma AG:
Available in Europe since 1996 and in Japan since 1999. Currently, the marketing situation is unclear. Levovist® is a first generation USCA consisting of galactose (milk sugar) ground into tiny crystals whose irregular surfaces act as nidation sites on which air pockets form when it is suspended in water, much as soda water bubbles form at small irregularities on the surface of the glass. A trace of palmitic acid is added as a surfactant to stabilize the resultant microbubbles. When Levovist® dissolves in blood, air trapped inside the galactose is released as free gas bubbles. These bubbles have a weak encapsulating shell and are easily destroyed by ultrasound. Different contrast ultrasonography methods have been developed since the introduction of Levovist®. Initially, Levovist® was an echo contrast medium for improving sensitivity in color Doppler and Power Doppler examinations, but was found to suffer from significant blooming, making it difficult to observe small blood vessels. However, Levovist® improves the accuracy of echocardiographic examinations in such indications as assessment of left ventricular function. In addition to their vascular phase, some ultrasound contrast agents (USCAs) can exhibit a tissue- or organ-specific phase. Levovist® can accumulate within the liver and the spleen for up to 20 min once it has disappeared from the blood pool and improves the detectability of focal liver lesions and allows more reliable control of interventional tumor treatments. Varied types of information can be obtained by applying contrast imaging at different times after the injection using Levovist® in both the arterial phase and the late organ-specific phase. 1 g Levovist® granules contain 999 mg D-galactose and 1 mg palmitic acid. Brand names in other countries: Levovist/Levograf
Drug Information and Specification
RESEARCH NAME
SHU 508A
DEVELOPER
INDICATION
APPLICATION
Intravenous injection
TYPE
Microbubble
Galactose/Palmitic acid
CHARGE
Negative
Air
MICROBUBBLE SIZE
95% < 10μm
PRESENTATION
Vials of 2.5 g and 4.0 g incl. one plastic ampoule containing 20 ml water for injection, one mini-spike and one disposable syringe of 20 ml
STORAGE
Room temp 15−30°C
PREPARATION
Reconstitute with 5 to 17 ml water
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT! •
(Perfluorocarbon exposed sonicated dextrose albumin) PESDA are sonicated dextrose albumin microbubbles containing decafluorobutane gas. PESDA is a sonicated self made contrast agent and not a commercial product. PESDA microbubbles can be used as a blood pool contrast agent in echocardiography to improve the detection of myocardial perfusion abnormalities.
Drug Information and Specification
RESEARCH NAME
-
DEVELOPER
-
INDICATION -
DEVELOPMENT STAGE APPLICATION
Intravenous injection
TYPE
Microbubble
Albumin / dextrose
CHARGE
-
Decafluorobutane
MICROBUBBLE SIZE
Mean: 4.7 ± 0.2 μm
PREPARATION
-
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT! Further Reading: Basics:
News & More: •
(PD) Power Doppler imaging (PDI) is a Doppler technique, sensitive to low blood flow, allowing a complete visualization of detailed vascular blood structure. This medical imaging method is useable for detecting microbubbles during myocardial contrast echocardiography. See also Resistive Index. Result Pages : |